# Biomea Fusion Announces Research Collaboration with University of Leicester to Evaluate Icovamenib in Combination with Semaglutide in Obesity
Canonical URL: https://biopharmsignal.com/news/BMEA/biomea-fusion-announces-research-collaboration-with-university-of-leicester-to-evaluate-icovamenib-in-combination-with-semaglutide-in-obesity
Ticker: BMEA
Company: Biomea Fusion
Source: Biomea Fusion
Published: 2026-06-25 13:46 EST
Original Source URL: https://investors.biomeafusion.com
## Summary

Collaboration will Assess the Potential Impact of the Combination of Icovamenib and Semaglutide on Physical Function, Body Weight, Body Composition, Muscle Health and Metabolic Outcomes Late-Breaking Preclinical Findings at the American Diabetes Association Annual Meeting June 5-8 Highlighting

## Article Body
Collaboration will Assess the Potential Impact of the Combination of Icovamenib and Semaglutide on Physical Function, Body Weight, Body Composition, Muscle Health and Metabolic Outcomes Late-Breaking Preclinical Findings at the American Diabetes Association Annual Meeting June 5-8 Highlighting
## Recent Company News
- 2026-06-25 13:46 EST — [Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association (“ADA”) 86th Scientific Sessions and Announces Expansion of Ongoing Phase I BMF-650 Study](https://biopharmsignal.com/news/BMEA/biomea-fusion-presents-new-clinical-and-translational-data-for-icovamenib-at-the-american-diabetes-association-ada-86th-scientific-sessions-and-announces-expansion-of-ongoing-phase-i-bmf-650-study) — Source: Biomea Fusion
- 2026-06-25 13:46 EST — [Biomea Fusion Announces Research Collaboration with University of Leicester to Evaluate Icovamenib in Combination with Semaglutide in Obesity](https://biopharmsignal.com/news/BMEA/biomea-fusion-announces-research-collaboration-with-university-of-leicester-to-evaluate-icovamenib-in-combination-with-semaglutide-in-obesity) — Source: Biomea Fusion
- 2026-06-25 13:46 EST — [Biomea Fusion Reports First Quarter 2026 Financial Results and Corporate Highlights](https://biopharmsignal.com/news/BMEA/biomea-fusion-reports-first-quarter-2026-financial-results-and-corporate-highlights) — Source: Biomea Fusion
- 2026-06-25 13:46 EST — [Biomea Fusion Presents COVALENT-111 Study Results at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)](https://biopharmsignal.com/news/BMEA/biomea-fusion-presents-covalent-111-study-results-at-the-23rd-world-congress-on-insulin-resistance-diabetes-and-cardiovascular-disease-wcirdc) — Source: Biomea Fusion
- 2026-06-25 13:46 EST — [Biomea Fusion Announces KOL Presentation and Interview on Menin and Icovamenib at WCIRDC 2025](https://biopharmsignal.com/news/BMEA/biomea-fusion-announces-kol-presentation-and-interview-on-menin-and-icovamenib-at-wcirdc-2025) — Source: Biomea Fusion
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)
- 2026-07-20 13:00 EST — ENLV — [Enlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 Billion](https://biopharmsignal.com/news/ENLV/enlivex-treasury-portfolio-update-nav-per-ordinary-share-66-16-total-treasury-ho-9d036ef9)